DARVON-N W Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Darvon-n W, and when can generic versions of Darvon-n W launch?
Darvon-n W is a drug marketed by Aaipharma Llc and is included in two NDAs.
The generic ingredient in DARVON-N W is aspirin; propoxyphene napsylate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; propoxyphene napsylate profile page.
US Patents and Regulatory Information for DARVON-N W
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aaipharma Llc | DARVON-N W/ ASA | aspirin; propoxyphene napsylate | CAPSULE;ORAL | 016829-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aaipharma Llc | DARVON-N W/ ASA | aspirin; propoxyphene napsylate | TABLET;ORAL | 016863-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
